Jump to navigation
Just published is a new OHE Consulting Report that explores society’s preferences across curative and non-curative therapies and large and small health gains.
This year, the OHE team published 39 peer reviewed journal articles, gave 58 lectures and conference presentations, posted 22 in-house OHE publications on our website, and hosted 6 lunchtime seminars and our annual lecture.
OHE publishes a report on the legal barriers to the better use of health data to deliver pharmaceutical innovation.
OHE Consulting produces a report on Measuring UK Medicines Expenditure in the Context of the 2014-18 PPRS.
This year marks the 70th birthday of the NHS. Our latest Consulting Report describes the most important new medicines as identified by experts.
OHE Consulting produces a report critiquing a paper by Hill et al. (2018) on estimated costs of production for the WHO Essential Medicines List.
OHE Consulting has produced a report summarising the literature on indication-based pricing and how it has been applied in the U.S. and 5 European countries.
A new OHE report discusses NICE’s introduction of a cost-effectiveness threshold to appraise ultra-orphan drugs.
OHE Consulting publishes a report on the barriers to the uptake of minimal access surgery in the NHS and private sector.
A recent paper examines EQ-5D-5L outcomes in patients with overactive bladder and compares them to results on the OAB-5D, a condition-specific measure.
Is Rate Of Return Pricing A Useful Approach When Value-Based Pricing Is Not Appropriate?
Exploring Variations in the Opportunity Cost Cost-effectiveness Threshold by Clinical Area: Results from a Feasibility Study in England
HTA in Japan: Failing to Meet International Good Practice?